- 全部删除
您的购物车当前为空
LY3200882 是一种高度选择性的、口服活性的、具有 ATP 竞争性的 TGF-β 受体 1 型 (ALK5) 抑制剂(IC50:38.2 nM)。它能够抑制多种促肿瘤活性,可用作免疫调节剂。


为众多的药物研发团队赋能,
让新药发现更简单!
LY3200882 是一种高度选择性的、口服活性的、具有 ATP 竞争性的 TGF-β 受体 1 型 (ALK5) 抑制剂(IC50:38.2 nM)。它能够抑制多种促肿瘤活性,可用作免疫调节剂。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 397 | In stock | |
| 5 mg | ¥ 993 | In stock | |
| 10 mg | ¥ 1,490 | In stock | |
| 25 mg | ¥ 2,670 | In stock | |
| 50 mg | ¥ 3,730 | In stock | |
| 100 mg | ¥ 5,320 | In stock | |
| 200 mg | ¥ 7,280 | In stock |
LY3200882 相关产品
| 产品描述 | LY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). |
| 靶点活性 | TGFβRI:38.2 nM (IC50) |
| 体外活性 | LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune cells. LY3200882 has shown anti-metastatic activity in vitro in migration assays. In in vitro immune suppression assays, LY3200882 has shown the ability to rescue TGFβ1 suppressed or T regulatory cell suppressed na?ve T cell activity and restore proliferation [1]. |
| 体内活性 | LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose-dependent fashion. LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer) [1]. |
| 分子量 | 435.52 |
| 分子式 | C24H29N5O3 |
| CAS No. | 1898283-02-7 |
| Smiles | CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1 |
| 密度 | 1.36 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| 溶解度信息 | DMSO: 4.36 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
评论内容